<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45012">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520323</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00095799</org_study_id>
    <nct_id>NCT02520323</nct_id>
  </id_info>
  <brief_title>The Lung Microbiome in Sarcoidosis</brief_title>
  <official_title>The Lung Microbiome in Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the presence of bacterial species, and the
      immunologic and molecular mechanisms of granuloma formation that might be involved in the
      pathogenesis of sarcoidosis. The investigators will collect peripheral blood and
      bronchoalveolar lavage fluid samples to isolate bacterial DNA and blood monocytes and
      lymphocytes. Specimens will be obtained from patients with sarcoidosis, with non-sarcoid
      lung disease, and healthy volunteers to directly compare the bacterial species present and
      the characteristics of cells thought to be involved in granuloma formation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome analysis</measure>
    <time_frame>Baseline</time_frame>
    <description>To assess the microbiome profile in lung lavage fluid and peripheral blood of subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of immunologic phenotype</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine whether the immune cell profile of sarcoidosis patients differs from healthy controls and other interstitial lung disease patients in blood and BAL fluid</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Blood only</arm_group_label>
    <description>20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood and BAL</arm_group_label>
    <description>10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <arm_group_label>Blood only</arm_group_label>
    <arm_group_label>Blood and BAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <arm_group_label>Blood and BAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <arm_group_label>Blood only</arm_group_label>
    <arm_group_label>Blood and BAL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential subjects will be patients with sarcoidosis (involving any organ system), with
        non-sarcoid interstitial lung disease, and healthy controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of sarcoidosis (30 subjects) or

          -  Clinical diagnosis of non-sarcoid interstitial lung disease (10 subjects) or

          -  Age-matched controls (30 subjects)

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Any disease condition (such as anemia, unstable cardiac disease, etc.) that in the
             opinion of the subject's primary physician would put the patient at risk of harm from
             having 60 cc of blood drawn or for undergoing bronchoscopy for this study.

          -  Patients who are undergoing bronchoscopy for presumed infection.

          -  Pregnant women, women who may be pregnant, and women who are breastfeeding.

          -  Patients who have undergone lung transplantation.

          -  Persons who are unable or unwilling to undergo bronchoscopy, including those unable
             to be accompanied by a designated driver to the procedure.

          -  Persons who have taken antibiotics in the 90 days prior to consent.

          -  Known HIV, HCV, alcohol, or other substance abuse history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric S White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric S White, MD</last_name>
    <phone>734-936-4000</phone>
    <email>docew@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric S White, MD</last_name>
      <phone>734-936-4000</phone>
      <email>docew@umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 10, 2016</lastchanged_date>
  <firstreceived_date>August 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Eric S. White, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
